DKDorothy Kenny

Dorothy Kenny

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dorothy Kenny has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Impact of Extracorporeal Membrane Oxygenation (ECMO) on Serum Concentrations of Cefepime

    by Christopher J. Destache, Raul Isern, Dorothy Kenny, Rima El-Herte, Robert Plambeck, Catherine Palmer, Brent S. Inouye, Maura Wong, E. Jeffrey North, Mariaelena Roman Sotelo, et al.

    ECMO is becoming widely used as a life-saving measure for critically ill patients. However, there is limited data on pharmacokinetics and the dosing of beta-lactam antibiotics in ECMO. In this study, we evaluated the serum concentrations of cefepime in patients on ECMO to determine the impact of ECMO circuitry and to guide therapeutic dosing. Methods: Patients 19 years or older admitted to the ICU, treated with ECMO and beta-lactam antibiotics for presumed or documented infection, were enrolled. Three blood samples (peak, midpoint, trough) were obtained before ECMO (pre-ECMO) and during ECMO (intra-ECMO) at a steady state. Results: Eight patients met inclusion criteria; six received cefepime. All patients were male. Average ± SD age was 45.8 ± 14.7. Four patients received ECMO for severe SARS-CoV-2 infection, and one each for Pneumocystis pneumonia and influenza A infection. Mean ± SD APACHE II and SOFA scores prior to ECMO were 24.6 ± 7.1 and 11.0 ± 3.9, respectively. All but one of the patients received venovenous (VV) ECMO. Cefepime 1 g every 6 h intravenously over 2 min was administered to all patients before and during ECMO. Cefepime concentrations were fit to non-compartment analysis (NCA) and area under the serum concentration–time curve averaged ± SE 211.9 ± 29.6 pre-ECMO and 329.6 ± 32.3 mg*h/L intra-ECMO, p = 0.023. No patients displayed signs of cefepime neurotoxicity. Patients received ECMO for 43.1± 30 days. All patients expired. Cefepime dosed at 1 g every 6 h intravenously appears to achieve therapeutic levels for critically ill patients on ECMO.


  • Open Access

    Impact of Extra-Corporeal Membrane Oxygenation (ECMO) on Serum Concentrations of Cefepime

    by Christopher J. Destache, Raul Isern, Dorothy Kenny, Rima El-Herte, Robert Plambeck, Catherine Palmer, Brent S Inouye, Maura Wong, Eldon Jeffrey North, Mari Roman Sotelo, et al.

    ECMO is becoming widely used as a life saving measure for critically ill patients. However, there is limited data on pharmacokinetics and dosing of beta-lactam antibiotics in ECMO. In this study, we evaluated the serum concentrations of cefepime in patients on ECMO to determine the impact of ECMO circuitry and to guide therapeutic dosing. Methods: Patients 19 years or older admitted to the ICU, treated with ECMO and beta-lactam antibiotics for presumed or docu-mented infection, were enrolled. Three blood samples (peak, midpoint, trough) were obtained before ECMO (pre-ECMO) and during ECMO (intra-ECMO) at steady state. Results: Eight pa-tients met inclusion criteria; six received cefepime. All patients were male. Average ±SD age was 45.8±14.7. Four patients received ECMO for severe SARS-CoV-2 infection, and one each for Pneumocystis pneumonia and influenza A infection. Mean ±SD APACHE II and SOFA scores prior to ECMO were 24.6±7.1 and 11.0±3.9, respectively. All but one received venovenous (VV) ECMO. Cefepime 1 gram every 6 hours intravenously over 2 minutes was administered to all patients before and during ECMO. Cefepime concentrations were fit to a one-compartment model and area under the serum-concentration time curve averaged ± SE 204.6 ± 51.2 pre-ECMO and 344.7 ± 51.5 mg*h/L intra-ECMO, p>0.05. No patients displayed signs of cefepime neurotoxi-city. Patients received ECMO for 43.1± 30 days. All patients expired. Cefepime dosed at 1 gram every 6 hours intravenously appears to achieve therapeutic levels for critically ill patients on ECMO.


  • Open Access

    Diagnosis and Outcomes of Fungal Co-Infections in COVID-19 Infections: A Retrospective Study

    by Richard Swaney, Rutendo Jokomo-Nyakabau, Anny A. N. Nguyen, Dorothy Kenny, Paul G. Millner, Mohammad Selim, Christopher J. Destache, Manasa Velagapudi

    The SARS-CoV-2 pandemic has resulted in a public health emergency with unique complications such as the development of fungal co-infections. The diagnosis of fungal infections can be challenging due to confounding imaging studies and difficulty obtaining histopathology. In this retrospective study, 173 patients with COVID-19 receiving antifungal therapy due to concern for fungal co-infection were evaluated. Patient characteristics, clinical outcomes, and the utility of fungal biomarkers were then evaluated for continuation of antifungal therapy. Data were collected from the electronic health record (EPIC) and analyzed using SPSS (version. 28, IBM, Inc., Armonk, NY, USA) Data are presented as mean ± SD or percentages. A total of 56 COVID-19 patients were diagnosed with fungal co-infection and 117 COVID-19 + patients had no fungal infection. Significantly fewer female patients were in the fungal+ group compared to COVID-19 control patients (29% in fungal+ compared to 51% in controls p = 0.005). Fungal diagnostics were all significantly higher in fungal+ patients. These include 1,4-beta-D-glucan (BDG), fungal culture, and bronchoalveolar lavage galactomannan (BAL GM). Intensive care unit hospitalization, mechanical ventilation, and mortality in fungal+ patients with COVID-19 were significantly higher than in control patients. Finally, significantly more fungal+ patients received voriconazole, isavuconazonium, or amphotericin B therapies, whereas control patients received significantly more short-course fluconazole. COVID-19+ patients with fungal co-infection were significantly more likely to be in the ICU and mechanically ventilated, and they result in higher mortality compared to control COVID-19 patients. The use of fungal diagnostics markers were helpful for diagnosis.


  • Open Access

    Unusual Freshwater-Related Infections Caused by Haematospirillum jordaniae

    by Zachary A Creech, Gia Thinh D. Truong, Dorothy X. Kenny, Dua Noor Butt, Changzhao Li, Stephen Cavalieri, Rima El-Herte

    Freshwater-related infections can be caused by a broad range of pathogens, potentially leading to skin and soft tissue, pulmonary, gastrointestinal, or even systemic diseases. Haematospirillum jordaniae (H. jordaniae), a gram-negative, aerobic organism previously regarded solely as an environmental microbe, has been classified as a pathogen capable of causing human infection in the United States. There has been only one other case reported in the literature of H. jordaniae infection, and little is known about the pathogenesis. The presentation and progression of clinical symptoms in our cases indicate freshwater cutaneous injury as the most likely route of H. jordaniae infection. We present two cases of H. jordaniae infection in elderly males. Both patients had freshwater exposure and skin injury resulting in sepsis, cellulitis at the site of injury, and bacteremia. Additionally, one patient presented with an acute deep venous thrombosis. The diagnosis of H. jordaniae was confirmed using Sanger sequencing 16s ribosomal RNA data. Antimicrobial therapy included piperacillin-tazobactam, ceftazidime, and levofloxacin. Both patients recovered successfully. While clinical cases and literature involving the newly classified human pathogen H. jordaniae are still rare, it is crucial to recognize the potential emergence of environmental organisms, previously believed to be harmless, as human pathogens. In cases of bacteremia and cellulitis with recent freshwater exposure and injury, H. jordaniae infection should be considered as part of the differential diagnosis.